

ZEJULA (niraparib)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

- 1. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers
 - a. Deleterious or suspected deleterious germline BRCA mutation, as determined by an FDA-approved test
 - b. Patient has had a complete or partial response to platinum-based chemotherapy
- 2. Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancers
 - a. Patient has had a complete or partial response to first-line platinumbased chemotherapy

AND ALL of the following for ALL indications:

- 1. Prescriber agrees to obtain a complete blood count (CBC) at baseline, weekly for the first month, and monthly thereafter
- 2. Prescriber agrees to monitor for cardiovascular effects
- 3. Females of reproductive potential **only**: prescriber agrees to advise patient to use effective contraception during therapy and for 6 months after the last dose

Prior - Approval Limits

Quantity 300 mg per day

Duration 12 months

Prior – Approval Renewal Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

- 1. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers
- 2. Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancers



ZEJULA (niraparib)

AND ALL of the following for ALL indications:

- 1. Prescriber agrees to obtain complete blood counts (CBCs) as clinically indicated
- 2. Prescriber agrees to monitor for cardiovascular effects
- 3. NO disease progression or unacceptable toxicity
- 4. Females of reproductive potential **only**: prescriber agrees to advise patient to use effective contraception during therapy and for 6 months after the last dose

Prior – Approval Renewal Limits

Same as above